In last trading session, Avadel Pharmaceuticals plc (NASDAQ:AVDL) saw 0.87 million shares changing hands with its beta currently measuring 1.80. Company’s recent per share price level of $18.82 trading at $0.52 or 2.84% at ring of the bell on the day assigns it a market valuation of $1.79B. That closing price of AVDL’s stock is at a discount of -1.17% from its 52-week high price of $19.04 and is indicating a premium of 49.52% from its 52-week low price of $9.50. Taking a look at company’s average trading volume volume of 1.20 million if we extend that period to 3-months.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
Upright in the green during last session for gaining 2.84%, in the last five days AVDL remained trading in the green while hitting it’s week-highest on Friday, 05/03/24 when the stock touched $18.82 price level, adding 1.41% to its value on the day. Avadel Pharmaceuticals plc’s shares saw a change of 33.29% in year-to-date performance and have moved 5.67% in past 5-day. Avadel Pharmaceuticals plc (NASDAQ:AVDL) showed a performance of 13.44% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
Statistics highlight that Avadel Pharmaceuticals plc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 82.36% of value to its shares in past 6 months, showing an annual growth rate of 77.00% while that of industry is 11.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 480.00% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 25.9M for the same. And 9 analysts are in estimates of company making revenue of 36.2M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.78% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 78.17% while estimates for its earnings growth in next 5 years are of 15.00%.
AVDL Dividends
Avadel Pharmaceuticals plc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
